Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

2(50.0%)

Phase 1

1(25.0%)

Phase 4

1(25.0%)

4Total

Phase 2(2)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05310968Phase 4Completed

Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction

Role: collaborator

NCT07334483Phase 2Recruiting

A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC

Role: lead

NCT07045428Phase 1Not Yet Recruiting

68Ga-GP-01 Injection in Solid Tumors Participants

Role: lead

NCT06712017Enrolling By Invitation

Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China

Role: lead

NCT06079242Not Yet Recruiting

Observational Study for SIR-Spheres Therapy for the Treatment of Unresectable Metastatic Liver Tumors From Primary Colorectal Cancer

Role: lead

NCT05188417Phase 2Unknown

A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke

Role: lead

All 6 trials loaded